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ABSTRACT 
Cardiovascular disease (CVD) is the largest single cause of mortality in human population and 
its major underlying pathology is atherosclerosis. Atherosclerosis is a chronic inflammatory 
disease that predisposes to coronary artery disease (CAD), stroke and peripheral arterial disease, 
responsible for most of the cardiovascular morbidity and mortality. It is an inflammatory 
process, triggered by the presence of lipids in the vascular wall, and encompasses a complex 
interaction among inflammatory cells, vascular elements, and lipoproteins through expression of 
several adhesion molecules and cytokines. Atherosclerosis is initiated by an accumulation of 
lipids, necrotic cells and fibrous elements in the neointima of medium and large arteries. Obesity 
per se is a strong risk factor for CVD. The pathophysiological mechanisms of the association 
between obesity and atherosclerosis are not fully understood. Altered levels of obesity related 
peptides such as ghrelin may play an important role in this pathophysiology. Recent evidence 
indicates that ghrelin feature a variety of cardiovascular activities, including increase of 
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myocardial contractility, vasodilatation, and protection from myocardial infarction. Recent 
literature data demonstrate that ghrelin can influence important key events in atherogenesis and 
thus they may play a role in atherosclerosis. In this review we present the latest data from recent 
performed animal and clinical studies which have focus on a novel approach to ghrelin as 
potential therapeutic agents in the treatment of complex disease such as atherosclerosis. Future 
investigations should now focus on the mechanisms of ghrelin actions which might present new 
approaches involved in the antiatherosclerotic effects revealed in this review. Thus, ghrelin may 
become a new therapeutic target for the treatment of some cardiovascular diseases. Further 
studies are necessary to investigate the potential mechanisms for the effects of ghrelin on 
cardiovascular system (CVS).  
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1. 
Cardiovascular disease (CVD), including coronary artery disease (CAD), stroke, and 
ischemia, are the leading single cause of morbidity and mortality in western world [
Introduction 
1, 2]. The 
major underlying pathological feature of these multifactorial diseases is atherosclerosis [2]. 
Atherosclerosis is a chronic inflammatory disease, described as occlusions of lipids 
andinflammatory cells within the intimal layer of vascular wall which results in endothelial cell 
injury and tissue dysfunction, leading to thickening and hardeningof the vessel wall [3]. 
Atherosclerotic plaque formation (hard structures in the walls) in small and large arteries, 
encompasses a complex interaction among vascular elements, inflammatory cells, and 
lipoproteins through expression of several adhesion molecules and cytokines [4]. Over time, 
these plaques can block the arteries and cause symptoms and problems throughout the body. It 
has become obvious that atherosclerosis is a multifactorial disease that involves not just genetic 
predisposition, but also environmental factors. Several already established factors contribute to 
the development of atherosclerosis [3]. The major risk factors for atherosclerosis are well-known 
and include high blood pressure, abnormal blood lipid profile (high total and low density 
lipoprotein (LDL) cholesterol and triglyceride concentrations and low high density lipoprotein 
(HDL) cholesterol concentration), smoking, physical inactivity, unhealthy diet (low intake of 
fruits and vegetables) and diabetes mellitus. In addition, the non-modifiable risk factors include 
advancing age, gender and family history of premature CAD. Importantly, inflammation is now 
believed to be a novel risk factor [5].  
Beside well known risk factors for the development of atherosclerosis, obesity has an 
important role to, but also, obesity, especially abdominal obesity, per se is a strong undependent 
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risk factor for CVD and many studies have shown the link betwen increased mortality and 
morbidity of CVD and obesity [6-11]. Overweight and obesity are defined as abnormal or 
excessive fat accumulation that presents a risk to health [12]. Obesity is a chronic multifactorial 
and complex disease, resulting from a long-term positive energy balance in wich bouth genetic 
and enviromental factors are involved [13-15]. It has been recently suggested that some forms of 
obesity are associated with chronic low-grade inflammation [13, 16]. The pathophysiological 
mechanisms of the association between obesity and atherosclerosis are not fully understood.  
It is possible that inflammation induced by obesity accelerates the atherosclerosis 
development [13]. Adipose tissue is recognized as an important player in obesity mediated CVD, 
becouse adipocytes produce large number of hormons, peptides and other molecules that effects 
cardiovascular system (CVS) function not only in endocrine manner, but also by autocrine and 
paracrine mechanisms [13, 17]. All this can lead to cytokine-mediated inflammatory changes in 
the liver, systemic infflamation and atherosclerosis [13]. Altered levels of obesity related 
peptides such as ghrelin, may play an important role in this pathophysiology [18]. 
Ghrelin is a gastric peptide hormone found in 1999. which has been shown to be 
associated with obesity. Ghrelin is consisting of 28 amino acids, among which the third amino 
acid Serin-3 (Ser3) is n-octanoylated, modified by a fatty acid and this modification is essential 
for ghrelin’s activity. Ghrelin is a growth hormone (GH) secretagogue which stimulates the 
release of GH from the pituitary and acts through the GHS-receptor (GHS-R), type 1a (GHS-
R1a) which is a G protein coupled receptor. The tissue distribution of ghrelin and GHS-R1a is 
widespread, but it is mainly produced in the stomach and GHS-R1a is mainly expressed in 
hypothalamus and in the pituitary, but GHS-R1a is also present in cardiomyocytes [19-21]. 
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 Recent evidence indicates that ghrelin, features a variety of cardiovascular activities, 
including increase of myocardial contractility, vasodilatation, and protection from myocardial 
infarction. It has been shown that ghrelin may have an important role in cardiovascular function, 
including regulation of atherosclerosis [22-25]. In addition, it has been shown that ghrelin 
stimulates appetite by acting on the hypothalamic arcuate nucleus, a region known to control 
food intake. Plasma ghrelin levels are decreased in obesity and increased under negative energy 
balance [26]. Ghrelin beside regulation of appetite affects secretion of gastric acid, gastric 
movement [20, 21]. Interestingly, ghrelin has been claimed to have anti-inflammatory actions 
that may have an important role in the development of atherosclerosis [27]. 
Favorable effects of ghrelin on the CVS have been shown both in humans and on animal 
models. Taking into consideration that ghrelin stimulates GH release, which earlier proved to 
have cardioprotective effects [28-30], ghrelin could possibly show favorable effects on CVS 
mediated through GH, but it could also show effects independent of GH effects [31-33]. It has 
been shown that ghrelin may improve cardiac function partly through GH dependent 
mechanisms but also, some evidence suggests that ghrelin's cardioprotective activity is 
independent from GH secretion[31-33]. It was earlier shown that GH has a favorable effect on 
the positive outcome in patients with heart disease [30].  
Present chapter reviews, in a concise form, the latest data from recent performed animal 
and clinical studies which have focus on a novel approach to ghrelin as potential therapeutic 
agents in the treatment of complex disease such as atherosclerosis.  
 
 
 
6 
 
2. 
Obesity and obesity related diseases are a major public health problem all around the 
world [
Ghrelin and obesity  
34]. The fundamental cause of obesity and overweight is an energy imbalance between 
calories consumed and calories expended [35, 36]. According to World Health Organization 
(WHO), overweight and obesity are the fifth leading cause for deaths on global level and 
considering its spreading it became a serious health problem and it is one of the major risk 
factors for the development of CVD like hypertension and atherosclerosis, and also diabetes [35]. 
The presence of obesity has been long associated with the presence of endothelial and 
vascular dysfunction, which provides partial explanation of how may obesity lead to CVD [34, 
37-39]. Obesity has many negative effects on the hemodynamic and also on the structure and 
function of the CVS [40]. In addition, in many epidemiological studies on obesity, it has been 
shown that obesity predisposes to CVD [36]. Although the associations of obesity and vascular 
dysfunction and vascular disorders have been unquestionably proven in large clinical trials, the 
exact mechanisms by which obesity leads to them, and therefore prospects for therapeutic 
interventions remain poorly explained [34]. 
Recent studies have shown that adipose tissue is not a simple energy storage organ, but 
exerts important endocrine and immune functions [34]. It is possible that alterations of immune 
function can link obesity to vascular disorders and risk factors for atherosclerosis [34, 41]. 
Indeed, recent data show that adipocytes as well as other cells present within fat tissues, are 
capable of releasing numerous novel and highly active molecules which acts as vasoactive 
factors leading to cardiovascular morbidity in obese individuals [34]. These adipocyte derived 
products exert significant effects on the immune system, thus modifying inflammation. These 
factors are termed “adipocytokines” in relation to fat tissue being their source [34, 42]. 
7 
 
Adipocytokines include several molecules released abundantly by adipocytes like leptin, resistin, 
adiponectin or visfatin, as well as some more classical cytokines released possibly by 
inflammatory cells infiltrating fat, like tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), 
monocyte chemotactic protein-1 (MCP-1/CCL2), interleukin 1 (IL-1) [43-47]. Evidence suggests 
that all of those molecules may act on immune cells leading to local and generalized 
inflammation and may also affect vascular (endothelial) function by modulating vascular nitric 
oxide (NO) and superoxide release and mediating obesity related vascular disorders including 
atherosclerosis and insulin resistance (IR) [34, 46, 48]. Thus, adipose tissue – it is no longer 
considered just an energy storage organ, but a real endocrine organ, hormones of which have not 
yet been fully characterized [34, 42]. In addition it becomes clear that adipose tissue is also, if not 
predominantly, an immune organ, and obesity related diseases like hypertension or 
atherosclerosis are in fact – immune disorders [34]. 
Also, one has to remember about other molecules involved in obesity, which are 
important in appetite control and adipocytes metabolism, which do not per se seem to originate 
from adipose tissue. There is also growing evidence suggesting that the development of obesity-
related disturbances may be closely associated with gastrointestinal (GI)  tract-derived hormonal 
dysregulation and chronic inflammation [27, 49-52]. One of such peptide is ghrelin, linking GI 
tract and satiety regulation to vascular function [34, 53], particularly that it is released in 
response to certain immune related stimuli [34, 54]. 
Ghrelin is a hormone which plays a very important role in the development of obesity 
and IR [25]. Among all discovered orexigenic peptide, ghrelin has been found to be the most 
powerful [20]. Ghrelin is the only known circulating orexigenic hormone that promotes adiposity 
[55]. Ghrelin is closely associated to energy homeostasis, weight regulation and obesity [56-61]. 
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Ghrelin is produced primarily in GI organs in response to hunger and circulates in the blood, 
serving as a peripheral signal telling the central nervous system to stimulate feeding. Ghrelin 
plasma levels are mainly regulated by nutritional and metabolic factors; in fact they are increased 
by energy restriction and decreased by food intake and overfeeding [62, 63]. Chronic 
intracerebroventricular injection of ghrelin increases cumulative food intake and decreases 
energy expenditure, resulting in body weight gain.  
Circulating plasma ghrelin levels are reportedly inversely associated with Body mass 
index (BMI) in humans [64-67]. It has been observed in several studies that obese individuals 
have lower circulating levels of ghrelin than non-obese individuals [26, 68] of same age and sex 
[69]. Furthermore, In humans, ghrelin secretion is decreased in obesity and is normalized 
following weight loss [60, 69, 70]. All forms of human obesity have inappropriately low ghrelin 
levels [63]. 
Exogenous administration of ghrelin is known to acutely increase food intake and chronic 
treatment greatly enhances body fat in rodents [56, 62]. When ghrelin is injected into the cerebral 
ventricles of rats, but also intravenously and subcutaneously, their food intake is potently 
stimulated [20, 56, 58, 59, 71-73]. These data indicate that ghrelin secretin in obesity is inhibited 
and it has been assumed that it may reflect a physiological adaptation to the positive energy 
balance associated with obesity [20, 69]. Careful prospective clinical studies during weight loss 
or weight gain are now needed to further clarify the role of the recently discovered hormone 
ghrelin in the pathogenesis of human obesity [69]. In addition, the role of hormones involved in 
energy homeostasis in CVS is still poorly understood. 
It has been shown that low ghrelin concentrations is associated with IR [68, 74-76]. In 
addition, recent literature suggests that besides food intake and energy balance, ghrelin also 
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controls glucose metabolism [77]. Furthermore, among obese subjects, plasma ghrelin levels are 
lower in IR persons compared to insulin sensitive persons [25, 78]. There is increasing amount of 
evidence that also ghrelin may have an important role in modulating function of adipose tissue 
[25].  
Considering that obesity has a significant role in modulati on of the ghrelin expression, it 
is very important to know how ghrelin is involved in the regulation of adipocyte metabolism 
[25]. Several studies have suggested that ghrelin may play an important role in adipogenesis and 
storage of energy in adipose tissue [25, 56, 79, 80].  
Kim et al. have shown that ghrelin has a direct mitogenic effect on 3T3-L1 preadipocytes 
[80]. The minimum effective concentration of ghrelin observed in these experiments was 
comparable to the circulating concentration in humans [26, 69], suggesting that, at physiological 
concentrations, ghrelin can act as an adipocyte mitogen [80]. In addition, Choi et al. find that 
ghrelin stimulated adipocyte differentiation in primary cultured rat adipocytes [81]. In visceral 
adipose tissue, ghrelin is shown to stimulate lipid accumulation by enhancing the expression of 
adipogenic genes including peroxisome proliferator-activated receptor gamma (PPAR)-γ, sterol 
regulatory element-binding protein (SREBP)-1, acetyl-CoA carboxylase, fatty acid synthase 
lipoprotein lipase, perilipin, adipocyte determination and differentiation-dependent factor 
(ADD)1, and adipose protein 2/fatty acid binding protein (aP2) during adipocyte  differentiation 
[25, 79, 80]. It is possible that these functions are mediated via AMP-activated protein kinase 
(AMPK) pathway [25, 82]. It has been also demonstrated that infusion of ghrelin modulates 
adipocyte metabolism by inhibiting isoproterenol induced lipolysis [83], regulating adipogenesis 
[84, 85], suppressing noradrenalin release in brown adipose tissue [86], and promoting glucose 
and triglyceride uptake and antiapoptotic actions [25, 80, 85]. Ghrelin has been also shown to 
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stimulate lipogenesis and to inhibit lipid oxidation in white adipocytes, whereas in brown 
adipocytes central ghrelin infusion results in decreased expression of uncoupling proteins, 
molecules contributing to energy dissipation [25, 85]. All of these findings strongly support the 
view that ghrelin may have an “energy saving” elects on adipose tissue [25]. In addition, ghrelin 
has also been shown to directly promote bone marrow adipogenesis in vivo [25, 85, 87]. 
However, Zang et al. have recently shown that ectopic overexpression of ghrelin gene in 3T3-L1 
cells promoted adipocyte proliferation but inhibited adipogenesis by stimulating cell proliferation 
[80, 87].  
Ghrelin has been demonstrated to interact with triglyceride-rich lipoproteins, HDL, very 
high-density lipoproteins, and to some extent with LDL [88, 89]. In population studies, plasma 
ghrelin concentrations have also been found to associate positively to HDL cholesterol levels and 
LDL particle size and negatively with LDL and triglyceride concentrations [90-93].  
Genetic variations in ghrelin and ghrelin receptor gene have been demonstrated to play a role in 
the determination of plasma levels of HDL-cholesterol in some populations, but this finding has 
not been duplicated in all populations [67, 94-96]. In addition, a contradictory positive 
association between plasma ghrelin levels and plasma LDL cholesterol has been found [97]. 
Recent investigations have demonstrated that ghrelin administration in rats can induce tissue-
specific changes in the expression of genes associated with mitochondrial and lipid metabolism 
and it can cause triglyceride deposition in the liver in preference to the skeletal muscle [98]. 
These interesting findings suggest that ghrelin indeed has a role in lipid metabolism. Further 
studies investigating the direct effect of ghrelin on lipid metabolism are definitely warranted. 
Thus, that ghrelin has proatherogenic alterations should be linked to involvement of ghrelin in 
obesity and atherosclerosis. 
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3. 
Atherosclerosis is a chronic inflammatory disease that predisposes to CAD, stroke and 
peripheral arterial disease, responsible for most of the cardiovascular morbidity and mortality 
[
Ghrelin and atherosclerosis 
99, 100]. It is an inflammatory process, triggered by the presence of lipids in the vascular wall, 
and encompasses a complex interaction among inflammatory cells, vascular elements, and 
lipoproteins through expression of several adhesion molecules and cytokines [4, 100]. 
Inflammation plays an important role in the pathogenesis of atherosclerosis [101]. Epidemiologic 
studies have identified environmental (stress, smoking, etc.) and genetic (dyslipidemia, type 2 
diabetes mellitus (T2DM), IR, and hypertension) risk factors predisposing to atherosclerosis [99]. 
Atherosclerosis is initiated by an accumulation of lipids, necrotic cells and fibrous elements in 
the neointima of medium and large arteries [102]. The major cells that contribute to 
atherosclerotic lesion formation are the endothelial cells (EC), vascular smooth muscle cells 
(VSMC) and macrophages [103-105]. The endothelium forms a permeable barrier between the 
blood and the vascular subendothelial space [99]. Whenever mechanical or chemical effectors 
weaken this barrier, a response is initiated [99]. Such activated EC produce several molecules 
which promote monocyte transmigration and subsequent differentiation in macrophages in the 
subendothelial space [102]. These events occur at the early stages of atherosclerosis [102]. 
Subsequently, VSMC proliferate and produce extracellular matrix components [106]. The 
activation of VSMC results in the release of pro-inflammatory cytokines, which, combined with 
the secretion of matrix metalloproteinases (MMP) and expression of pro-coagulant factors, 
results in a chronic inflammation [106]. Atherosclerosis progresses to a pathologic condition 
when this clearance pathway becomes inefficient, and the presence of a large lipid core in the 
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atherosclerotic lesion correlates with the severity of the pathology [99]. Key features of rupture-
prone unstable plaques are a thinned fibrous cap overlying a large necrotic core in the setting of 
an active inflammatory infiltrate [107]. Atherosclerotic plaque rupture is caused by a 
combination of plaque biomechanical forces that are dependent on the fibrous cap thickness, 
necrotic core thickness, and the extent of positive coronary arterial remodeling [100, 108]. 
It has been shown that ghrelin may have and important role in cardiovascular function, 
including regulation of atherosclerosis [22]. One study showed that the plasma concentration of 
ghrelin had a positive correlation with development of carotid artery atherosclerosis in males, but 
not in females [22, 109]. Animal studies suggest that ghrelin receptors were significantly up-
regulated (3-4 fold) in both atherosclerotic coronary arteries and saphenous vein grafts with 
advanced intimal thickening, when compared with normal vessels [110, 111]. However, a 
research on kidney transplant patients demonstrates that lower plasma ghrelin concentration is an 
independent marker for abnormalities in glucose homeostasis, which is related to greater carotid 
intima-media thickness (cIMT) [112], a well-established surrogate marker for atherosclerosis. 
Furthermore, findings in older subjects with metabolic syndrome (MS) demonstrate that cIMT is 
significantly inversely correlated with ghrelin levels [113] and in elderly hypertensives des-acyl 
ghrelin had a significant inverse correlation with cIMT [22, 114]. The effects of ghrelin on 
increased cIMT, which is a surrogate marker to the development of atherosclerosis, remain to be 
fully elucidated [113]. The study done by Kotani et al. suggests that ghrelin might play a role in 
increased cIMT, independently with age and systolic blood pressure (BP), in older subjects with 
MS [113]. Positive associations between cIMT and both age and BP in this study are basically 
consistent with prior findings of studies on MS [113, 115, 116]. Further research with a 
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perspective design and a larger sample size is needed to clarify the causal role of ghrelin in 
carotid atherosclerosis [113]. 
On the whole, ghrelin and its receptors participate in the occurrence and development of 
the atherosclerotic process, and elevations of both levels may represent a compensatory 
mechanism to reverse the process, while, in kidney transplant patients and older people with MS 
or hypertension, this compensatory ability may be lost or damaged, of course, this deduction 
need further confirmation [22]. So far, the potential regulating mechanism of ghrelin on 
atherosclerosis is not clear [22]. 
Endothelial dysfunction is considered to be one of the earliest events of the 
atherosclerotic development. In patients with endothelial dysfunction, plasma ghrelin level 
decreases [22, 117]; conversely, the application of exogenous ghrelin can improve endothelial 
dysfunction in MS patients by increasing NO bioactivity [118]. In addition, atherosclerosis is 
linked to inflammation and immunological reaction [22]. Studies found that, ghrelin can inhibit 
proinflammatory cytokine pro-duction, mononuclear cell binding, and nuclear factor-kappa B 
(NF-κB) activation in human endothelial cells in vitro as well as endotoxin induced cytokine 
production in vivo [119], moreover, exogenous ghrelin may significantly inhibit TNF-α/ 
interferon-γ-induced CD40 expression in human umbilical vein EC (HUVEC) cells in a 
concentration-dependent manner [22, 120].  
Ghrelin inhibits proinflammatory cytokine production, mononuclear cell binding, and 
NF-κB activation in human endothelial cells in vitro and endotoxin-induced cytokine production 
in vivo [119]. These novel antiinflammatory actions of ghrelin suggest that the peptide could play 
a modulatory role in atherosclerosis, especially in obese patients, in whom ghrelin levels are 
reduced [119]. In the recent study, reported by authors examined the effects of ghrelin on 
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inflammatory responses in cultured HUVECs and in vivo after endotoxin administration [119]. 
Their findings provide the first evidence that ghrelin acts as an antiinflammatory peptide in the 
cardiovascular system [119]. Li et al. demonstrate for the first time that ghrelin has potent 
antiinflammatory effects in HUVECs, likely mediated by inhibition of NF-κB activation [119]. 
Ghrelin also inhibited endotoxin-induced systemic cytokine production in vivo [119]. Findings 
reported by the same authors may help to explain the beneficial effects of ghrelin administration 
in various pathological states associated with inflammation, including experimental models of 
heart failure and septic shock [119]. Moreover, their findings suggest that a reduction in 
endogenous ghrelin could contribute to the increased incidence of atherosclerosis in patients with 
obesity [119]. 
  Since ghrelin is an effective vasodilator [109, 121], it has been suggested that the change 
in the receptor density might reflect the beneficial role of ghrelin in human atherosclerosis [109, 
110]. On the other hand, a recent study has demonstrated nonbeneficial vasoconstrictive actions 
of ghrelin [122]. To clarify these contrasting findings, Poykko et al. characterized the association 
between ghrelin concentrations and atherosclerosis in humans [109]. The major finding of their 
study was that plasma ghrelin concentrations associated positively with the degree of subclinical 
atherosclerosis [109]. First, the beneficial haemodynamic effect and vasoactive role of ghrelin 
has been demonstrated both in vitro [121] and in vivo [123] as well as in association studies [68, 
109]. Western blot analysis demonstrated that treatment with ghrelin increased endothelial NO 
synthase (eNOS) expression in the aorta of GH-deficient rats [33]. Furthermore, it has been 
reported that administration of ghrelin improves endothelial dysfunction and increases eNOS 
expression in rats through GH-independent mechanisms [33, 124]. Administration of ghrelin may 
be a new therapeutic approach to the treatment of endothelial impairment and may contribute to 
15 
 
the prevention of atherosclerosis [33]. Low ghrelin concentrations have been associated with 
metabolic disturbances such as IR, T2DM, and MS [68, 109], which are commonly recognized as 
risk factors of atherosclerosis [109]. Data indicate that although reductions of both plasma 
desacyl ghrelin and plasma high-molecular weight (HMW) adiponectin are associated with 
obesity, only the former is a useful cardiometabolic marker for predicting atherosclerosis in 
elderly hypertensives [114]. Although therewas a significant association between the des-acyl 
ghrelin and NO levels, the association of des-acyl ghrelin with atherosclerosis appears to be 
independent of the NO level [114].  
Recent data document that ghrelin inhibits angiotensin II (Ang II) induced contraction 
and proliferation in human aortic smooth muscle cells (HASMC), and thus it is involved in 
VSMC regulation [125]. In the vascular system, binding sites are present in aorta, peripheral 
arteries and veins, and their density is increased in atherosclerosis and in the atheromasic plaque 
[111, 125]. In addition, ghrelin was reported to lower blood pressure in vivo by inducing 
vasodilatation of resistance vessels [126]. Recent data, reported by Rossi et al. show that ghrelin 
affects Ang II-induced contraction of HASMC, and that this inhibition is mediated by ghrelin 
binding to a specific receptor and subsequent activation of the cyclic adenosine monophosphate 
(cAMP)/protein kinase A (PKA) pathway [125]. Findings are consistent with the vasodilatory 
effect reported in vivo by Okumura et al. [127] and document for the first time the relaxing effect 
exerted by ghrelin on HASMC, and suggest that it is mediated by cAMP/PKA pathway 
activation [125]. In addition Rossi et al. showed that ghrelin, per se, did not affect HASMC 
proliferation, but it showed the capability to antagonize Ang II-induced HASMC proliferation, in 
a dose-dependent manner and via GHS-R1a receptor [125]. The antiproliferative effect seems to 
be mainly mediated by the cAMP pathway [125]. This is consistent with cAMP pathway 
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activation being documented to inhibit proliferation induced by Ang II and several other 
agonists, which is mediated by protein kinase C (PKC), extracellular-signal-regulated kinase 
(ERK 1/2) and protein kinase B (Akt) [128-130]. This data document that ghrelin affects several 
HASMC functions, opening the way to consider ghrelin as a possible therapeutic target in many 
pathological conditions associated with vascular damage and remodeling, and not only in those 
associated with decreased circulating ghrelin levels [125].  
 
4. 
The literature facts that we have taken into consideration, as well as our published and 
preliminary results, relating to protective effects of ghrelin on CVS, suggest that ghrelin could be 
one of the essential therapeutic molecules in the treatment of cardiac dysfunction and disease. 
Future investigations should now focus on the mechanisms of ghrelin actions which might 
present new approaches involved in the antiatherosclerotic effects revealed in this chapter. Thus, 
ghrelin may become a new therapeutic target for the treatment of some CVD. It is therefore of 
great importance to understand molecular mechanisms, which represent the foundation of ghrelin 
effects on CVS, both in physiological, and pathophysiological states. Further studies are 
necessary to investigate the potential mechanisms for the effects of ghrelin on CVS. Elucidation 
of the precise mechanism by which ghrelin regulates atherosclerosis may provide key insights 
into ghrelin’s administration in atherosclerosis therapy [
Conclusion 
22]. 
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